(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 24.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Aurinia Pharmaceuticals's revenue in 2025 is $235,133,000.On average, 3 Wall Street analysts forecast AUPH's revenue for 2025 to be $35,472,333,070, with the lowest AUPH revenue forecast at $35,131,320,293, and the highest AUPH revenue forecast at $35,859,217,078. On average, 3 Wall Street analysts forecast AUPH's revenue for 2026 to be $48,038,441,016, with the lowest AUPH revenue forecast at $41,036,897,981, and the highest AUPH revenue forecast at $60,118,780,864.
In 2027, AUPH is forecast to generate $62,044,273,868 in revenue, with the lowest revenue forecast at $51,309,856,378 and the highest revenue forecast at $72,778,691,359.